Arrow Therapeutics has nailed down a big licensing deal with Novartis on A604444, an experimental treatment for Respiratory Syncytial Virus. Novartis will pay $10 million up front and up to $217 million more in milestones for a successful development program. Novartis also gains first-rights to the bargaining table for additional molecules in follow-up development at Arrow.
"A-60444 is a first-in-class product for the treatment of RSV," says Arrow CEO Ken Powell. "This is an area of high unmet medical need, and one which is gaining increasing recognition of its importance by the medical community. For Arrow in particular, the deal with Novartis is a validation of both our model and our R&D capability and I am very satisfied with the outcome."
- read this release for more